Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements

• Status: Available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Christine Hunter; Joseph Jankovic
• Treatments: Tetrabenazine

Criteria

Inclusion Criteria:

• Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.

• Willing to sign informed consent.

• Willing to comply with procedures required as part of this study.

Exclusion Criteria:

• Those subjects unwilling to comply with study requirements.

• Subjects unable to give informed consent.